Home Cart Sign in  
Chemical Structure| 64-02-8 Chemical Structure| 64-02-8
Chemical Structure| 64-02-8

*Storage: Sealed in dry,Room Temperature.

*Shipping: Normal

Ethylenediaminetetraacetic acid tetrasodium

CAS No.: 64-02-8

Ethylenediaminetetraacetic acid tetrasodium functions similarly to sodium hydrate, acting as a metal chelator with the same range of biological activities and applications.

Synonyms: EDTA tetrasodium

4.5 *For Research Use Only !

Cat. No.: A304078 Purity: 98% (Loss on drying≤10%)

Change View

Size Price

USA Stock *0-1 Day

Global Stock *5-7 Days

In Stock
25g łÇǶÊÊ In Stock In Stock Login
100g łÇÿ¶ÊÊ In Stock In Stock Login
500g łÇî¶ÊÊ Inquiry In Stock Login

Please Login or Create an Account to: See VIP prices and availability

  • 25g

    łÇǶÊÊ

  • 100g

    łÇÿ¶ÊÊ

  • 500g

    łÇî¶ÊÊ

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Product Details of [ 64-02-8 ]

CAS No. :64-02-8
Formula : C10H12N2Na4O8
M.W : 380.17
SMILES Code : [O-]C(CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)=O.[Na+].[Na+].[Na+].[Na+]
Synonyms :
EDTA tetrasodium
MDL No. :MFCD00150027
InChI Key :UEUXEKPTXMALOB-UHFFFAOYSA-J
Pubchem ID :6144

Safety of [ 64-02-8 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302+H332-H318-H373
Precautionary Statements:P260-P264-P270-P271-P280-P301+P312+P330-P304+P340+P312-P305+P351+P338+P310-P314-P501

Calculated chemistry of [ 64-02-8 ] Show Less

Physicochemical Properties

Num. heavy atoms 24
Num. arom. heavy atoms 0
Fraction Csp3 0.6
Num. rotatable bonds 11
Num. H-bond acceptors 10.0
Num. H-bond donors 0.0
Molar Refractivity 55.29
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

167.0 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

-49.43
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-5.88
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-7.41
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-1.79
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.44
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

-13.39

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

2.23
Solubility 65100.0 mg/ml ; 171.0 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

3.04
Solubility 420000.0 mg/ml ; 1110.0 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.53
Solubility 12900.0 mg/ml ; 33.9 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

Low
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-12.79 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

2.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

1.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<2.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.14

Application In Synthesis [ 64-02-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 64-02-8 ]

[ 64-02-8 ] Synthesis Path-Downstream   1~1

  • 1
  • [ 6086-21-1 ]
  • [ 109-72-8 ]
  • tetrakis (triphenylphosphine) palladium (O) [ No CAS ]
  • [ 64-02-8 ]
  • [ 108857-18-7 ]
  • [ 108857-09-6 ]
YieldReaction ConditionsOperation in experiment
Zinc chloride; In tetrahydrofuran; hexane; water; EXAMPLE 4 7-(<strong>[6086-21-1]1-Methyl-1,2,4-triazol</strong>-5-yl)-1,2,3,5-tetrahydroimidazo(2,1-b)-quinazolin-2-(1H)-one, H2 O STR13 n-Butyl lithium (6.6 cm3 of a 1.6M solution in n-hexane) was added to a stirred solution of 1-methyl-1,2,4-triazole (0.83 g) in THF (20 cm3) at -70° under nitrogen. After stirring for 1 hour at -70° the white syspension was treated with a solution of anhydrous zinc chloride (4.1 g) in THF (20 cm3) and the mixture was warmed to room temperatue. 7-Iodo-1,2,3,5-tetrahydroimidazo(2,1-b)quinazolin-2-(1H)-one (1.33 g) and tetrakis (triphenylphosphine)palladium (O) (0.05 g) were added and the mixture was heated under reflux for 6 hours. The cooled solution was evaporated in vacuo and the residue partitioned between dichloromethane:methanol, 9:1 (200 cm3), and a solution of ethylenediaminetetraacetic acid disodium salt (10 g) in water (200 cm3). The aqueous phase was further extracted with dichloromethane:methanol, 9:1 (2*150 cm3), and the combined and dried (MgSO4) organic phases were evaporated in vacuo to give a solid which was chromatographed on silica (Merck "MK 60.9385" [Trade Mark]) eluding with chloroform:methanol:aqueous ammonia (S.G. 0.880), 90:10:1. Combination and evaporation of appropriate fractions afforded a solid (0.36 g) which was recrystallized from chloroform-methanol to give the title compound, m.p. 340°-343° (0.16 g). Analysis percent: Found: C,54.7; H,4.3; N,28.9; Calculated for C13 H12 N6 O.H2 O: C,54.5; H,4.9; N,29.4.
 

Related Products

Historical Records